Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
QMCO enters the final stretch of October carrying three distinct tailwinds: short sellers are quietly covering, index trackers are almost certainly forced buyers in November and December, and a cluster of insiders collected fresh stock grants just days ago.
The short position tells a story of gradual retreat. At 14.8% of the free float, short interest remains elevated, but it has fallen 8% over the past week and is down roughly 3% over the past month. The lending market offers no friction for anyone wanting to add a short: availability has surged to around 1,411%, meaning there are more than fourteen shares available to borrow for every one already lent out. Cost to borrow is just 0.56%, near its lowest in months and down 10% on the week. With shorts covering, borrow loose and costs negligible, the short-side pressure that characterised earlier in the year has materially eased. The ORTEX short score has drifted down to 39.5, from above 44 at the end of September, reflecting that declining conviction. Options are similarly relaxed: the put/call ratio of 0.18 is marginally below its 20-day average of 0.19, squarely in neutral territory, with no meaningful skew toward protection.
The index rebalance calendar is the most concrete near-term catalyst on the register. ORTEX forecasts a 95% probability of QMCO joining the MSCI USA IMI, MSCI USA Small, MSCI World IMI and MSCI World Small indices at the November 2026 Quarterly Review, with announcement expected on November 11 and trades settling December 1. The combined flow across those additions is around $42M per index. Separately, ORTEX puts the chance of Russell 2000 and Russell 3000 additions at 76%, with the December Semi-Annual Review announcement on November 13 and a trade date of December 11. The Russell addition alone implies $146M of forced buying, equivalent to roughly 2.8 days of normal volume. The stock, at $30.43, is already 88% above the Russell entry price line of $3.66, so the qualifying threshold is not in doubt. In past comparable Russell additions, median performance from announcement to effective date was minus 4%, with 55% of names moving the expected way and trade-day volume running at 8.8 times normal. That is history, not a forecast, but it frames the risk around the event dates.
On the ownership side, the activist register carries three Schedule 13D filers, and one dominates. John Fichthorn holds approximately 40% of the company as last disclosed, filing a 13D/A in June 2026 after building from 41.4%. That concentration is significant: when a single 13D holder commands 40% of shares, day-to-day float is narrower than headline share counts suggest, which partly explains why even a modest 14.8% short position reads as high relative to the tradeable float. Two other 13D filers, Blue Torch Capital and Pacific Investment Management, have both materially reduced or exited their positions since early 2025, suggesting the earlier restructuring-era activist pressure has cleared. Alyeska Investment Group and Oaktree Capital have since filed passive 13G positions at 6.7% and 5.1% respectively, signalling institutional accumulation at higher prices. As always with 13D/G filings, stakes are as-last-disclosed around the 5% threshold and positions can change without a further filing.
October 1 brought a wave of insider award grants: the Chief Operating Officer received 150,000 shares, the Chief Accounting Officer 50,000, and five directors each received 12,000 shares. These are transaction code "A" grants, not open-market purchases, so they carry less direct conviction signal than discretionary buying. The most recent open-market activity in the last 90 days was net selling: the CEO sold 6,232 shares in July at $10.51, a price less than a third of where the stock trades today. That context is worth holding alongside the grant activity.
The analyst picture is thin and slightly dated. Lake Street raised its target to $29 in mid-September, maintaining a Buy rating, which at the time was above the then-current price but now sits below the $30.43 close. The consensus mean target of $26.50 is also below the current price, a reversal that reflects how sharply the stock has run since August, when it posted a one-day gain of over 61% on earnings. The next print is due November 11, the same day as the MSCI announcement, making that date the first real convergence point for all three threads: index confirmation, earnings reaction, and how the short base responds to whichever way the numbers land.
See the live data behind this article on ORTEX.
Open QMCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
